Navigation Links
Norovirus, AIDS vaccine and Hepatitis Virus

ch 2005 issue of the Journal of Virology.

Hepatitis B (HBV) and C (HCV) are viruses that infect the liver, and in some cases can cause liver failure requiring a transplant for survival. The protein interferon, produced by animal cells when they are invaded by viruses, is released into the bloodstream or intercellular fluid to induce healthy cells to manufacture an enzyme that counters the infection. One class of interferons (alpha) is used to treat chronic infection with HBV and HCV. There is a vaccine available to prevent the spread of HBV but not HCV.

In the study, a new class of interferons, interferon lambda, was tested for its ability to inhibit HBV and HCV replication. Results showed 90% inhibition of HBV after twenty-four hours and 90-99% inhibition in HCV five days posttreatment.

"We have demonstrated here that replication of HBV and HCV is sensitive to the antiviral activities of interferon lambda," say the researchers. "These results suggest the possibility that interferon lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection."

(M.D. Robek, B.S. Boyd, F.V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology, 79. 6: 3851-3854.)


'"/>

Source:American Society for Microbiology


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. HIV vaccine trial breaks ground for future research
7. Live vaccines more effective against horse herpes virus
8. NIAID begins clinical trial of West Nile virus vaccine
9. Designing vaccines by computer
10. Wake Forest scientists find new combination vaccine effective against plague
11. New vaccine means bye-bye to bacteria in the lung
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Norovirus AIDS vaccine and Hepatitis Virus

(Date:9/2/2014)... history of scientific research on mountain ecosystems, looks ... and sets an agenda for biodiversity conservation throughout ... gloom and mountain glory revisited: A survey of ... appears online in the Journal of Mountain ... Tufts University, Jodi A. Hilty of the Wildlife ...
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... R.I. [Brown University] It,s hard to comprehend how ... world has become without knowing what it was before ... pre-human rate was 10 times lower than scientists had ... times worse. , Extinctions are about 1,000 times more ... people came along. The explanation from lead author Jurriaan ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... A University of Utah biologist and an international research team ... hope for new ways to attack the major pest, which ... The voracious mites, which technically are not insects, can ... The mites, newly revealed and sequenced genome contains a variety ...
... of Illinois at Chicago College of Medicine describe for ... checkpoint enzymes that must be chemically modified to enable ... thought to play a key role in cancer and ... Nature Structural and Molecular Biology . Telomeres are ...
... recent opening of its new Biomolecular Labeling Laboratory, the ... one of a small handful of facilities in the ... isotopes to make them easier to analyze. The new ... in biomedical fields who also want to take advantage ...
Cached Biology News:Big pest, small genome 2Big pest, small genome 3Big pest, small genome 4UIC study identifies a key molecular switch for telomere extension by telomerase 2Tags? We're it. NIST opens new 'biolabeling' research facility 2
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... 13 /PRNewswire-Asia/ -- IVT Corporation announced today that,it will demonstrate ... Hong Kong on Nov. 18-19, at Booth F08, and CES ... reducing risk of diseases and,assisting with emergency rescue. , ... It includes: , 1) ...
... Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:,SSRX) ("3SBio" or ... developing, manufacturing and marketing,biopharmaceutical products, today announced its unaudited ... , , Third Quarter 2009 Financial ... by 35.8% over the third quarter of 2008 to, ...
... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 33SBio Inc. Announces Unaudited Third Quarter 2009 Results 43SBio Inc. Announces Unaudited Third Quarter 2009 Results 53SBio Inc. Announces Unaudited Third Quarter 2009 Results 63SBio Inc. Announces Unaudited Third Quarter 2009 Results 73SBio Inc. Announces Unaudited Third Quarter 2009 Results 83SBio Inc. Announces Unaudited Third Quarter 2009 Results 93SBio Inc. Announces Unaudited Third Quarter 2009 Results 103SBio Inc. Announces Unaudited Third Quarter 2009 Results 113SBio Inc. Announces Unaudited Third Quarter 2009 Results 123SBio Inc. Announces Unaudited Third Quarter 2009 Results 133SBio Inc. Announces Unaudited Third Quarter 2009 Results 143SBio Inc. Announces Unaudited Third Quarter 2009 Results 153SBio Inc. Announces Unaudited Third Quarter 2009 Results 163SBio Inc. Announces Unaudited Third Quarter 2009 Results 173SBio Inc. Announces Unaudited Third Quarter 2009 Results 183SBio Inc. Announces Unaudited Third Quarter 2009 Results 193SBio Inc. Announces Unaudited Third Quarter 2009 Results 203SBio Inc. Announces Unaudited Third Quarter 2009 Results 21AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: